GALC and Krabbe disease: Considering these data, recent findings that ICM administration of high dose AAV9-CAGGS-GALC (1x1014 vg) prior to disease onset in a naturally occurring canine model for Krabbe disease decreased psychosine concentration and inflammation, improved myelination, nerve conduction and extended lifespan from 16 weeks to at least 2.5 years are very promising (Bradbury et al., 2020).